A study on the safety, reactogenicity and immune response of a vaccine against influenza in healthy younger and older adults

Trial Identifier:	217895
Sponsor:	GlaxoSmithKline
Collaborator:	CureVac AG
Start Date:	August 2022
Primary Completion Date:	March 2024
Study Completion Date:	March 2024
Condition:	Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Canada, NS	Halifax, NS, Canada, B3J 3G9

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.